Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction

International Journal of Impotence Research

Volumn 16, Issue 1, 2004, Pages 51-59

  Diamond, L E ^a   Earle, D C ^a   Rosen, R C ^b   Willett, M S ^c   Molinoff, P B ^a  

^a Palatin Technologies   (United States)

^b RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c Advanced Biomedical Research Inc   (United States)

Author keywords

Erectile dysfunction; Melanocortin; PT 141

Indexed keywords

HEPTAPEPTIDE; MELANOCORTIN; MELANOCORTIN RECEPTOR; N ACETYLNORLEUCYLASPARTYLHISTIDYL DEXTRO PHENYLALANYLARGINYLTRYPTOPHYLLYSINE 2,7 CYCLIC AMIDE; PLACEBO; SILDENAFIL; TADALAFIL; UNCLASSIFIED DRUG; VARDENAFIL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RESPONSE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; ERECTILE DYSFUNCTION; FLUSHING; HEADACHE; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; PATIENT SATISFACTION; PENILE BLOOD FLOW; PENIS ERECTION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SOMNOLENCE; TASTE DISORDER; VASCULAR ENDOTHELIUM; VOMITING;

ADMINISTRATION, INTRANASAL; ADOLESCENT; ADULT; ALPHA-MSH; DOUBLE-BLIND METHOD; HUMANS; IMPOTENCE; MALE; MIDDLE AGED; PENILE ERECTION; PEPTIDES, CYCLIC; PLACEBOS; RECEPTORS, MELANOCORTIN; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 1642483808     PISSN: 09559930     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ijir.3901139     Document Type: Article

References (21)

1. Krane RJ, Goldstein I, Saenz De Tejada I. Impotence. N Engl J Med 1989; 321: 1648-1659.
2. NIH Consensus Conference. Impotence. JAMA 1993; 270: 83-90.
3. Furlow WL. Prevalence of impotence in the United States. Med Aspects Hum Sex 1985; 19: 13-16.
4. Kaiser FE. Erectile dysfunction in the aging man. Med Clin N Am 1999; 83: 1267-1278.
5. Goldstein I et al. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998; 338: 1397-1404.
6. Padma-Nathan H, Steers WD, Wicker PA. Efficacy and safety of oral sildenafil in the treatment of erectile dysfunction: a double-blind, placebo-controlled study of 329 patients. Int J Clin Pract 1998; 52: 375-379.
7. Stark S et al. Vardenafil increases penile rigidity and tumescence in men with erectile dysfunction after a single oral dose. Eur Urol 2001; 40: 181-190.
8. Kuan J, Brock G. Selective phosphodiesterase type 5 inhibition using tadalafil for the treatment of erectile dysfunction. Expert Opin Invest Drugs 2002; 11: 1605-1613.
9. Wessells H et al. Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction. Urology 2000; 56: 641-646.
10. Rosen RC et al. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822-830.
11. Rosen RC, Cappelleri JC, Gendrano N. The International Index of Erectile Function (IIEF): a state-of-the-science review. Int J Impot Res 2002; 14: 226-244.
12. Dula E, Bukofzer S, Perdok R, George M, Apomorphine SL Study Group. Double-blind, crossover comparison of 3 mg apomorphine SL with placebo and with 4 mg apomorphine SL in male erectile dysfunction. Eur Urol 2001; 39: 558-564.
13. Heaton JPW, Dean J, Sleep DJ. Sequential administration enhances the effect of pomorphine SL in men with erectile dysfunction. Int J Impot Res 2002; 14: 61-64.
14. Wikberg JE et al. New aspects on the melanocortins and their receptors. Pharmacol Res 2000; 42: 393-420.
15. Argiolas A, Melis MR, Murgia S, Schioth HB. ACTH- and alpha-MSH-induced grooming, stretching, yawning and penile erection in male rats: site of action in the brain and role of melanocortin receptors. Brain Res Bull 2000; 51: 425-431.
16. Argiolas A, Melis MR, Gessa GL. Yawning and penile erection: central dopamine-oxytocin-adrenocorticotropin connection. Ann NY Acad Sci 1988; 525: 330-337.
17. Van der Ploeg LHT, Martin WJ, Howard AD, Nargund RP. A role for the melanocortin 4 receptor in sexual function. Proc Natl Acad Sci USA 2002; 99: 11381-11386.
18. Udelson D et al. Axial penile buckling forces vs Rigiscan radial rigidity as a function of intracavernosal pressure: why Rigiscan does not predict functional erections in individual patients. Int J Impot Res 1999; 11: 327-337.
19. Licht MR, Lewis RW, Wollan PC, Harris CD. Comparison of RigiScan and sleep laboratory nocturnal penile tumescence in the diagnosis of organic impotence. J Urol 1995; 154: 1740-1743.
20. Kaneko S, Bradley WE. Evaluation of erectile dysfunction with continuous monitoring of penile rigidity. J Urol 1986; 136: 1026-1029.
21. Ogrinc FG, Linet OI. Evaluation of real-time RigiScan monitoring in pharmacological erection. J Urol 1995; 154: 1356-1359.